The role of positron emission tomography (PET) in the management of lymphoma patients.

[1]  J Kotzerke,et al.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Gerundini,et al.  Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  A. Buck,et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography , 1998, European Journal of Nuclear Medicine.

[4]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[5]  J. D. van der Walt,et al.  Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.

[6]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[7]  F. Lomeña,et al.  67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. , 1997, Nuclear medicine communications.

[8]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[9]  M E Phelps,et al.  Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  D. Zelterman,et al.  Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Gherlinzoni,et al.  Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. , 1996, Leukemia & lymphoma.

[12]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[13]  P. Zinzani,et al.  Hodgkin's disease: controversies and challenges for the future. , 1991, Haematologica.

[14]  S. Minoshima,et al.  The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  G. Scambia,et al.  High dose chemotherapy with cisplatin, VP16 and carboplatin with stem cell support in patients with advanced ovarian cancer. , 1991, Haematologica.

[16]  H. Minn,et al.  PET and [11C]methionine in assessment of response in non-Hodgkin lymphoma , 1990, The Lancet.

[17]  L. Nadler,et al.  Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. , 1988, Seminars in hematology.

[18]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[19]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[20]  J S Fowler,et al.  A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  G. Bonadonna,et al.  Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. , 1977, Cancer treatment reports.

[22]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[25]  S. Reske,et al.  Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma , 1999, European Journal of Nuclear Medicine.

[26]  F. Gherlinzoni,et al.  Diagnostic role of gallium scanning in the management of lymphoma with mediastinal involvement. , 1999, Haematologica.

[27]  G. Jerusalem,et al.  Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.

[28]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.